English system diabetes switch news about members investors cellnovo profile press releases documentation media cellnovo on stock market investor contacts investors cellnovo profile Based in France and the United Kingdom, Cellnovo is an innovative medical device company specialising in diabetes. Cellnovo has developed and markets the first connected all-in-one diabetes management system based on a patch pump that helps make life easier for patients. With its unique device Cellnovo allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time. The system has CE mark, is reimbursed in most countries and is already being marketed in France and the United Kingdom. Operating on the most dynamical market segment, Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to cope with the expected high level of demand. In July 2015, Cellnovo joined the Euronext regulated market in Paris, in compartment C, raising €31.56 million through a capital increase. financial calendar Events Date * 2015 Q3 sales Thursday October 22nd, 2015 2015 FY sales Wednesday January 20th, 2016 2015 FY results and 2016 Q1 sales Wednesday April 27th. 2016 Annual Shareholders Meeting Friday June 24th, 2016 2016 H1 sales Wednesday July 20th, 2016 2016 H1 results Thursday September 22nd, 2016 2016 Q3 sales Thursday October 20th, 2016 * Subject to modification. Press releases are published after market closes. shareholding structure press releases Financial Calendar Cellnovo expands its organisation 09/10/2015 Cellnovo expands partnership with Flex as it begins high-volume manufacturing of its connected all-in-one diabetes management system 29/09/2015 Full exercise of the overallotment option 16/07/2015 Success of Cellnovo's IPO with €31.6 million raised on Euronext in Paris 09/07/2015 Cellnovo launches its IPO on the Euronext regulated market in Paris 29/06/2015 Cellnovo Starts the Expansion of its Distribution Network 19/06/2015 Cellnovo Joins the Diabeloop© Artificial Pancreas Development Programme 17/06/2015 PR registration of document de base 03/02/2015 documentation Securities note 29/06/2015 Cellnovo document de base 03/02/2015 media cellnovo in the media Media coverage in French video Day In The Life of a Diabetic cellnovo on stock market Cellnovo on Euronext Paris ISIN: FR0012633360 Mnemonic: CLNV Stock Market: Euronext Paris, Compartment C Share Price analyst coverage Arsène GUEKAM Delphine LE LOUET Samuel HOSSEINI investor contacts Cellnovo Sophie Baratte investors@cellnovo.com Didier Le Normand investors@cellnovo.com NewCap Investor Relations - Emmanuel Huynh Phone : +33 (0)1 44 71 94 94 / cellnovo@newcap.fr Our Vision Leadership Cellnovians Contact privacy policy info@cellnovo.com +44 (0) 203 058 1250 © copyright 2012 Cellnovo